SEK 0.42
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very poor margins and returns
Data is available to registered users only
Data is available to registered users only
About
Based in Copenhagen, Denmark, 2cureX AB (publ) is a European medtech firm established in 2006. The company's core offering is IndiTreat, an in-vitro diagnostic test designed to forecast how cancer patients will respond to or resist various drug treatments, thereby guiding clinicians in selecting the most effective therapy. Additionally, 2cureX is actively advancing IndiTreat through clinical programs targeting a range of cancers, including breast, colorectal, ovarian, and pancreatic types.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Data is available to registered users only